Skip to content

Clinical Trial for the Assessment of Delayed Antibiotic Treatment in Pediatric (DAP-Pediatrics)

Clinical Trial for the Assessment of Delayed Antibiotic Treatment in the Non-complicated Acute Respiratory Tract Infections in Pediatric (Study DAP-Pediatrics)

Status
Completed
Phases
Phase 4
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT01800747
Acronym
DAP
Enrollment
450
Registered
2013-02-28
Start date
2012-06-30
Completion date
2016-06-07
Last updated
2017-07-31

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Acute Bronchitis, Acute Otitis Media, Pharyngotonsillitis, Rhinosinusitis

Keywords

Delayed antibiotic treatment, Acute respiratory infections, Pediatrics, Satisfaction

Brief summary

The general hypothesis is that delayed antibiotic treatment strategy present similar effectiveness, when compared with non-prescription of antibiotics or the prescription of antibiotics, in the non-complicated acute respiratory tract infections in pediatric patients.

Detailed description

The current project (DAP Pediatrics) is a study that explores the optimization of antibiotic prescribing in our country by evaluating the delayed prescription of antibiotics. The proposed trial will take place in the context of a prior similar study we conducted in adults. The study currently underway is the DAP-Adults study (a randomised controlled trial that evaluates several antibiotic prescribing strategies, including de delayed prescription in uncomplicated acute respiratory infections in adults in primary care). The aim of this study DAP-Pediatrics (randomized, multicenter parallel) to determine the efficacy and safety of delayed prescription of antibiotics compared to direct prescription and non-prescription of antibiotic in uncomplicated acute respiratory infections in pediatric patients. This 3 arms clinical trial will include 450 children and will evaluate the duration and severity of symptoms, antibiotic consumption, parents' satisfaction, the perceived efficacy of antibiotics and the number of visits generated. The project also includes a qualitative study, by means of structured interviews, to assess the perception and attitudes of parents towards the different treatment strategies and carry out a full analysis of economic evaluation.

Interventions

The patients enrolled will be randomized between three treatment strategies or arms. Patients randomized to delayed treatment arm or direct treatment, doctors can choose the antibiotic that they consider appropriate depending on such local resistance or practice.

Sponsors

Instituto de Salud Carlos III
CollaboratorOTHER_GOV
Ministry of Health, Spain
CollaboratorOTHER_GOV
Asociacion Colaboracion Cochrane Iberoamericana
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
NONE

Intervention model description

Antibiotic treatment versus delayed antibiotic treatment

Eligibility

Sex/Gender
ALL
Age
2 Years to 14 Years
Healthy volunteers
No

Inclusion criteria

General Inclusion Criteria: In this study can be enrolled children (2 to 14 ages) with non-complicated acute respiratory tract infections, including pharyngotonsillitis, rhinosinusitis, acute bronchitis and acute media otitis. The doctors include children with these infections if they have reasonable doubts if they should treat with antibiotics. General

Exclusion criteria

* Patients not aged between 2 and 14. * Patients have participated in the DAP-pediatrics previously. * Patients are severely affected or patients has been felt severely affected for one week (all time). * Patients with symptoms and signs suggestive of serious illness or severely affected and/or complications (particularly pneumonia, mastoiditis, peritonsillar abscess, peritonsillar cellulitis, intraorbital or intracranial complications). * Patients at high risk of serious complications due to prior comorbidity. This includes significant heart disease, lung, kidney, liver or neuromuscular, immunosuppression, cystic fibrosis.

Design outcomes

Primary

MeasureTime frameDescription
Duration and severity of symptoms30 daysCoordination Centre performed telephone interviews.

Secondary

MeasureTime frameDescription
Antibiotic consumption30 daysSelf-reported by the patients and checked at the Regional Pharmacy's Units.
Parents satisfaction with treatment30 daysLikert scale.
Impact of DAP strategy on the reconsultation1 yearMedical history review
The prescription of antibiotics in the previous two years predicts the effect of prescribing strategies in reconsultation.1 yearMedical history review
Parents' belief in the efficacy of antibiotics30 daysLikert scale

Other

MeasureTime frameDescription
Complications of disease30 daysIncluded by doctors or coordination centre

Countries

Spain

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 10, 2026